JP2019521184A - 糖尿病および他の変性慢性複合疾患によって生じる慢性損傷促進性細胞老化を元の状態に戻すおよび予防するための、代謝バイオエネルギー調節因子とニュートラエピジェネティック調節因子の組合せ、従来技術とナノテクノロジーを組み合わせた栄養補助化合物 - Google Patents

糖尿病および他の変性慢性複合疾患によって生じる慢性損傷促進性細胞老化を元の状態に戻すおよび予防するための、代謝バイオエネルギー調節因子とニュートラエピジェネティック調節因子の組合せ、従来技術とナノテクノロジーを組み合わせた栄養補助化合物 Download PDF

Info

Publication number
JP2019521184A
JP2019521184A JP2019517750A JP2019517750A JP2019521184A JP 2019521184 A JP2019521184 A JP 2019521184A JP 2019517750 A JP2019517750 A JP 2019517750A JP 2019517750 A JP2019517750 A JP 2019517750A JP 2019521184 A JP2019521184 A JP 2019521184A
Authority
JP
Japan
Prior art keywords
diabetes
formulation
ppm
composition
regulators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019517750A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019521184A5 (enExample
Inventor
デ ラ ベガ、 オラシオ アストゥディージョ
デ ラ ベガ、 オラシオ アストゥディージョ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority claimed from PCT/MX2017/000061 external-priority patent/WO2017213486A2/es
Publication of JP2019521184A publication Critical patent/JP2019521184A/ja
Publication of JP2019521184A5 publication Critical patent/JP2019521184A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2019517750A 2015-06-08 2017-06-08 糖尿病および他の変性慢性複合疾患によって生じる慢性損傷促進性細胞老化を元の状態に戻すおよび予防するための、代謝バイオエネルギー調節因子とニュートラエピジェネティック調節因子の組合せ、従来技術とナノテクノロジーを組み合わせた栄養補助化合物 Pending JP2019521184A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562172339P 2015-06-08 2015-06-08
US15/176,422 2016-06-08
US15/176,422 US10285963B2 (en) 2015-06-08 2016-06-08 Combination of metabolic bio-energetic and nutra-epigentic regulators, nutraceutical compounds in conventional and nanotechnologies combination to revert and prevent the chronic damage accelerated cellular senescence produced by diabetes and other degenerative chronic complex diseases
MXMX/A/2017/007448 2017-06-07
MX2017007448A MX365886B (es) 2015-06-08 2017-06-07 Combinación de reguladores metabólicos bioenergéticos y nutra-epigenéticos, compuestos nutracéuticos en combinaciones convencionales y nanotecnológicas para revertir y prevenir la senescencia celular acelerada por daño crónico producida por diabetes y otras enfermedades complejas crónico-degenerativas.
PCT/MX2017/000061 WO2017213486A2 (es) 2016-06-08 2017-06-08 Combinación de reguladores metabólicos bioenergéticos y nutra-epigenéticos, compuestos nutracéuticos en combinaciónes convencionales y nanotecnológicas para revertir y prevenir la sesencencia celular acelerada por daño crónico producida por diabetes y otras enfermedades complejas crónico-degenerativas

Publications (2)

Publication Number Publication Date
JP2019521184A true JP2019521184A (ja) 2019-07-25
JP2019521184A5 JP2019521184A5 (enExample) 2020-07-27

Family

ID=57450744

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019517750A Pending JP2019521184A (ja) 2015-06-08 2017-06-08 糖尿病および他の変性慢性複合疾患によって生じる慢性損傷促進性細胞老化を元の状態に戻すおよび予防するための、代謝バイオエネルギー調節因子とニュートラエピジェネティック調節因子の組合せ、従来技術とナノテクノロジーを組み合わせた栄養補助化合物

Country Status (8)

Country Link
US (1) US10285963B2 (enExample)
JP (1) JP2019521184A (enExample)
CN (1) CN109890369B (enExample)
BR (1) BR112018075395A2 (enExample)
CA (1) CA3027048A1 (enExample)
ES (1) ES2988151T3 (enExample)
MX (1) MX365886B (enExample)
RU (1) RU2749950C2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3470060B1 (en) * 2016-06-08 2024-07-31 Astudillo De La Vega, Horacio Composition comprising resveratrol, glycine, arginine and cysteine for use in treating metabolic syndrome

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006273834A (ja) * 2004-06-28 2006-10-12 Kao Corp Ａｍｐｋ活性化剤
JP2009543756A (ja) * 2005-07-19 2009-12-10 アクティメックス エス．アール．エル． 抗酸化活性が改善された微量養分を含有する組成物及びその使用
JP2011132151A (ja) * 2009-12-22 2011-07-07 Kirin Holdings Co Ltd 脂質代謝改善用組成物
JP2012041296A (ja) * 2010-08-19 2012-03-01 Medience Corp 血管内皮機能改善剤、一酸化窒素産生促進剤、及び飲食品

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7709539B2 (en) * 2004-08-11 2010-05-04 Chang Gung University Therapeutic use of resveratrol for hyperglycemia
WO2007035612A2 (en) * 2005-09-16 2007-03-29 Ordway Research Institute, Inc. Polyphenol conjugates as rgd-binding compounds and methods of use
JPWO2008143182A1 (ja) * 2007-05-17 2010-08-05 株式会社カネカ 甘草ポリフェノールを含有する組成物
EP3466418A1 (en) * 2011-07-15 2019-04-10 NuSirt Sciences, Inc. Compositions and methods for modulating metabolic pathways

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006273834A (ja) * 2004-06-28 2006-10-12 Kao Corp Ａｍｐｋ活性化剤
JP2009543756A (ja) * 2005-07-19 2009-12-10 アクティメックス エス．アール．エル． 抗酸化活性が改善された微量養分を含有する組成物及びその使用
JP2011132151A (ja) * 2009-12-22 2011-07-07 Kirin Holdings Co Ltd 脂質代謝改善用組成物
JP2012041296A (ja) * 2010-08-19 2012-03-01 Medience Corp 血管内皮機能改善剤、一酸化窒素産生促進剤、及び飲食品

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SHI, Y.-W., ET AL., MOLECULAR NUTRITION FOOD RESEARCH, vol. 56, no. 9, JPN6021015270, 2012, pages 1433 - 1444, ISSN: 0004649846 *

Also Published As

Publication number Publication date
RU2018147077A3 (enExample) 2020-09-21
ES2988151T3 (es) 2024-11-19
CN109890369B (zh) 2022-04-29
BR112018075395A2 (pt) 2019-04-02
US10285963B2 (en) 2019-05-14
CA3027048A1 (en) 2017-12-14
MX365886B (es) 2019-06-19
CN109890369A (zh) 2019-06-14
US20160354331A1 (en) 2016-12-08
RU2018147077A (ru) 2020-07-10
RU2749950C2 (ru) 2021-06-21
MX2017007448A (es) 2018-09-10

Similar Documents

Publication Publication Date Title
Kamal et al. Beneficial health effects of glucosinolates-derived isothiocyanates on cardiovascular and neurodegenerative diseases
Inchingolo et al. Benefits and implications of resveratrol supplementation on microbiota modulations: a systematic review of the literature
Superti et al. Alpha-lipoic acid: biological mechanisms and health benefits
Li et al. Reduction of aging-induced oxidative stress and activation of autophagy by bilberry anthocyanin supplementation via the AMPK–mTOR signaling pathway in aged female rats
Liu et al. Dietary polyphenols as anti-aging agents: targeting the hallmarks of aging
Turska et al. A review of the health benefits of food enriched with kynurenic acid
Zhou et al. Tetrahydroxystilbene glucoside extends mouse life span via upregulating neural klotho and downregulating neural insulin or insulin-like growth factor 1
JP2011178728A (ja) Ａｍｐｋ活性化剤、ｇｌｕｔ４活性化剤、およびそれらを用いた医薬品・飲食品
Salucci et al. Extra virgin olive oil (EVOO), a Mediterranean diet component, in the management of muscle mass and function preservation
Xue et al. HGSD attenuates neuronal apoptosis through enhancing neuronal autophagy in the brain of diabetic mice: The role of AMP-activated protein kinase
US10039798B2 (en) Extracts of rosemary or hemerocallis fulva and methods of using same to promote circadian rhythm
Park et al. The inhibition of autophagy and pyroptosis by an ethanol extract of Nelumbo nucifera leaf contributes to the amelioration of dexamethasone-induced muscle atrophy
Makarov et al. Differential role of active compounds in mitophagy and related neurodegenerative diseases
Minuti et al. Role and functions of irisin: a perspective on recent developments and neurodegenerative diseases
JP2024036620A (ja) 認知機能改善剤
Mirzababaei et al. Saccharomyces Boulardii alleviates neuroinflammation and oxidative stress in PTZ-kindled seizure rat model
Mirhashemi et al. Effect of two herbal polyphenol compounds on human amylin amyloid formation and destabilization
JP2010518117A (ja) シンドロームｘ関連の危険因子を低減または除去する方法および材料
Niewiadomska et al. Effects of Punica granatum L. peel extract supplementation on body weight, cardiac function, and haematological and biochemical parameters in an animal model of metabolic syndrome
JP2019521184A (ja) 糖尿病および他の変性慢性複合疾患によって生じる慢性損傷促進性細胞老化を元の状態に戻すおよび予防するための、代謝バイオエネルギー調節因子とニュートラエピジェネティック調節因子の組合せ、従来技術とナノテクノロジーを組み合わせた栄養補助化合物
ES2661579A1 (es) Composición para el control del peso a través de la modulación de los niveles de péptidos involucrados en saciedad y/o apetito.
EP3470060B1 (en) Composition comprising resveratrol, glycine, arginine and cysteine for use in treating metabolic syndrome
Ming et al. Inhibitory effect of Garlic Powder on MPTP-induced dopaminergic neurodegeneration by activation of Nrf2-HO1 and mitochondrial dynamics
OA19128A (en) Combination of metabolic regulators and nutraceuticals for the prevention of chronic damage from diabetes.
HK40010029A (en) Combination of metabolic regulators and compounds for preventing and reducing the severity of chronic damage caused by diabetes

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200608

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200610

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210511

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210810

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211018

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211130